Home » Stocks » VNDA

Vanda Pharmaceuticals Inc. (VNDA)

Stock Price: $17.95 USD -0.79 (-4.22%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $17.76 -0.19 (-1.05%) Mar 2, 4:54 PM
Market Cap 985.14M
Revenue (ttm) 248.17M
Net Income (ttm) 23.34M
Shares Out 54.43M
EPS (ttm) 0.42
PE Ratio 42.74
Forward PE 30.30
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $17.95
Previous Close $18.74
Change ($) -0.79
Change (%) -4.22%
Day's Open 18.72
Day's Range 17.85 - 18.72
Day's Volume 585,606
52-Week Range 7.12 - 20.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Investors Business Daily - 2 weeks ago

The IBD SmartSelect Composite Rating for Vanda Pharmaceuticals increased from 78 to 97 Friday. The post Vanda Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared ...

PRNewsWire - 2 weeks ago

WASHINGTON, Feb. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended Decembe...

PRNewsWire - 1 month ago

WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, Febru...

The Motley Fool - 3 months ago

The biotech's sleep drug Hetlioz gained an expanded approval.

24/7 Wall Street - 3 months ago

News of an update from the U.S. Food and Drug Administration (FDA) pushed Vanda Pharmaceuticals Inc.

PRNewsWire - 3 months ago

WASHINGTON, Dec. 1, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) ...

GuruFocus - 3 months ago

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, SRGA, PETS, SRDX
Seeking Alpha - 4 months ago

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GuruFocus - 4 months ago

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBI...

Other stocks mentioned: CPRX, PRDO, SBR, XBIT
PRNewsWire - 4 months ago

WASHINGTON, Oct. 28, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020. "V...

PRNewsWire - 4 months ago

WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational Ne...

PRNewsWire - 4 months ago

WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020, a...

Investopedia - 5 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, TECH, XBIT
PRNewsWire - 6 months ago

WASHINGTON, Aug. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

24/7 Wall Street - 6 months ago

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) took another big step forward in the fight against COVID-19 on Tuesday morning.

PRNewsWire - 6 months ago

WASHINGTON, Aug. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Seeking Alpha - 6 months ago

Vanda Pharmaceuticals Is Still Undervalued Despite Strong Performance During The Pandemic

Seeking Alpha - 6 months ago

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

PRNewsWire - 7 months ago

WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, af...

Zacks Investment Research - 7 months ago

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals I...

Zacks Investment Research - 7 months ago

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

PRNewsWire - 7 months ago

WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in ...

Investopedia - 8 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, TRIL, VRTX, XBIT
Benzinga - 8 months ago

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

PRNewsWire - 9 months ago

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss ...

PRNewsWire - 9 months ago

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharm...

The Motley Fool - 9 months ago

No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.

The Motley Fool - 9 months ago

Third-quarter results from a COVID-19 trial could send this stock soaring.

Seeking Alpha - 9 months ago

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 10 months ago

Vanda Pharmaceuticals: Undervalued Despite Its COVID-19 Treatment Potential

Zacks Investment Research - 10 months ago

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infe...

CNBC Television - 10 months ago

Vanda Pharmaceutical CEO on coronavirus vaccine

Dr. Mihael Polymeropoulos, Vanda Pharmaceuticals CEO, joins "Closing Bell" to discuss the latest updates on the coronavirus.

Seeking Alpha - 1 year ago

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

Other stocks mentioned: FHN, JHG, PCG, PFG, TCRD
Seeking Alpha - 1 year ago

Vanda Loses Against The FDA, And Other News: The Good, Bad, And Ugly Of Biopharma

GuruFocus - 1 year ago

On the tailwind of a growing U.S. economy, in which gross domestic product is projected to have hit a 2% annualized gain in the final quarter of 2019, the Russell 2000 Index rose 25.8% to $1,6...

Other stocks mentioned: FORM, IRBT
Seeking Alpha - 1 year ago

Vanda: Significantly Underappreciated

Forbes - 1 year ago

These five stocks should benefit from the “January bounce” that often buoys up the previous year’s losers.

Other stocks mentioned: CNX, CPS, CXO, GDOT
GuruFocus - 1 year ago

Energy stocks, and to a lesser extent bank stocks, have been the market’s whipping boys in 2019.

Other stocks mentioned: CNX, CPS, CXO, GDOT
Seeking Alpha - 1 year ago

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.

Benzinga - 1 year ago

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) received a negative FDA verdict on its drug Hetlioz, the company said Monday.

24/7 Wall Street - 1 year ago

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares dropped early to begin the week after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administ...

Benzinga - 1 year ago

Small-cap biopharma Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has withstood the market-wide sell-off witnessed in early August, thanks to the second-quarter report the company issued July 31.

Zacks Investment Research - 1 year ago

Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

About VNDA

Vanda Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of b... [Read more...]

Industry
Biotechnology
IPO Date
Apr 12, 2006
CEO
Mihael Polymeropoulos
Employees
292
Stock Exchange
NASDAQ
Ticker Symbol
VNDA
Full Company Profile

Financial Performance

In 2020, VNDA's revenue was $248.17 million, an increase of 9.23% compared to the previous year's $227.19 million. Earnings were $23.34 million, a decrease of -79.80%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for VNDA stock is "Buy." The 12-month stock price forecast is 21.00, which is an increase of 16.99% from the latest price.

Price Target
$21.00
(16.99% upside)
Analyst Consensus: Buy